Last reviewed · How we verify
trabodenoson 3.0% QD
trabodenoson 3.0% QD is a Adenosine A1 receptor agonist Small molecule drug developed by Inotek Pharmaceuticals Corporation. It is currently in Phase 3 development for Treatment of glaucoma. Also known as: INO-8875.
Trabodenoson is a selective adenosine A1 receptor agonist.
Trabodenoson 3.0% is being studied as a potential treatment for Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT) in combination with latanoprost. The exact mechanism of trabodenoson is not specified in the provided information, but it is being investigated in a fixed-dose combination with latanoprost in a Phase II clinical trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | trabodenoson 3.0% QD |
|---|---|
| Also known as | INO-8875 |
| Sponsor | Inotek Pharmaceuticals Corporation |
| Drug class | Adenosine A1 receptor agonist |
| Target | Adenosine A1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By activating the adenosine A1 receptor, trabodenoson is thought to reduce intraocular pressure in patients with glaucoma. This is achieved through a decrease in aqueous humor production and an increase in uveoscleral outflow.
Approved indications
- Treatment of glaucoma
Common side effects
- Headache
- Eye pain
- Eye irritation
Key clinical trials
- Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG (PHASE2)
- Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trabodenoson 3.0% QD CI brief — competitive landscape report
- trabodenoson 3.0% QD updates RSS · CI watch RSS
- Inotek Pharmaceuticals Corporation portfolio CI
Frequently asked questions about trabodenoson 3.0% QD
What is trabodenoson 3.0% QD?
How does trabodenoson 3.0% QD work?
What is trabodenoson 3.0% QD used for?
Who makes trabodenoson 3.0% QD?
Is trabodenoson 3.0% QD also known as anything else?
What drug class is trabodenoson 3.0% QD in?
What development phase is trabodenoson 3.0% QD in?
What are the side effects of trabodenoson 3.0% QD?
What does trabodenoson 3.0% QD target?
Related
- Drug class: All Adenosine A1 receptor agonist drugs
- Target: All drugs targeting Adenosine A1 receptor
- Manufacturer: Inotek Pharmaceuticals Corporation — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of glaucoma
- Also known as: INO-8875
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing